top
Search terms
Results 1 - 8 of 8 - ordered by :
Ehjournal

Abstract Aims ASSENT 3 (Assessment of the Safety and Efficacy of a New Thrombolytic) demonstrated that the bolus fibrinolytic tenecteplase (TNK), combined with enoxaparin (ENOX) or abciximab (ABCX), ...

European Heart Journal, Armstrong, Paul W., Wagner, Galen, Goodman, Shaun G., Van de Werf, Frans, Granger, Christopher, Wallentin, Lars, Fu, Yuling

Date : 01/08/2003 Item size : 146465 bytes
Ehjournal

At that point, left ventricular hypertrophy (LVH) can lead to deleterious cardiovascular effects such as ventricular dysfunction, impaired coronary perfusion, and disturbances in cardiac rhythm.1 LVH ...

European Heart Journal, Westerhout, Cynthia M., Lauer, Michael S., James, Stefan, Fu, Yuling, Wallentin, Lars, Armstrong, Paul W.

Date : 01/09/2007 Item size : 274844 bytes
Ehjournal

Abstract Aims Serial forecasts of final myocardial infarct (MI) size during fibrinolytic treatment (Rx) of ST-elevation MI would allow the identification of high-risk patients with a predicted major ...

European Heart Journal, Johanson, Per, Fu, Yuling, Goodman, Shaun G., Dellborg, Mikael, Armstrong, Paul W., Krucoff, Mitchell W., Wallentin, Lars, Wagner, Galen S.

Date : 01/09/2005 Item size : 208287 bytes
Ehjournal

Abstract Aims ASSENT 3 (Assessment of the Safety and Efficacy of a New Thrombolytic) demonstrated that the bolus fibrinolytic tenecteplase (TNK), combined with enoxaparin (ENOX) or abciximab (ABCX), ...

European Heart Journal, Armstrong, Paul W., Wagner, Galen, Goodman, Shaun G., Van de Werf, Frans, Granger, Christopher, Wallentin, Lars, Fu, Yuling

Date : 01/08/2003 Item size : 146421 bytes
Ehjournal

Methods and results In 6066 STEMI patients enrolled in the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial with complete electrocardiographic data, we assessed the ...

European Heart Journal, Chang, Wei-Ching, Kaul, Padma, Fu, Yuling, Westerhout, Cynthia M., Granger, Christopher B., Mahaffey, Kenneth W., Wallentin, Lars, Van de Werf, Frans, Armstrong, Paul W.

Date : 01/02/2006 Item size : 180042 bytes
Ehjournal

Abstract Aims ASSENT 3 (Assessment of the Safety and Efficacy of a New Thrombolytic) demonstrated that the bolus fibrinolytic tenecteplase (TNK), combined with enoxaparin (ENOX) or abciximab (ABCX), ...

European Heart Journal, Armstrong, Paul W., Wagner, Galen, Goodman, Shaun G., Van de Werf, Frans, Granger, Christopher, Wallentin, Lars, Fu, Yuling

Date : 01/08/2003 Item size : 183515 bytes
Ehjournal

Methods and results In 6066 STEMI patients enrolled in the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial with complete electrocardiographic data, we assessed the ...

European Heart Journal, Chang, Wei-Ching, Kaul, Padma, Fu, Yuling, Westerhout, Cynthia M., Granger, Christopher B., Mahaffey, Kenneth W., Wallentin, Lars, Van de Werf, Frans, Armstrong, Paul W.

Date : 01/02/2006 Item size : 191570 bytes
Ehjournal

At that point, left ventricular hypertrophy (LVH) can lead to deleterious cardiovascular effects such as ventricular dysfunction, impaired coronary perfusion, and disturbances in cardiac rhythm.1 LVH ...

European Heart Journal, Westerhout, Cynthia M., Lauer, Michael S., James, Stefan, Fu, Yuling, Wallentin, Lars, Armstrong, Paul W.

Date : 01/09/2007 Item size : 265649 bytes